THE ROLE OF ARTIFICIAL INTELLIGENCE IN BIOINFORMATICS: BIOLOGICAL DATABASES AND DATA ANALYSIS (2024-2025)

Abstract

This paper explores the rapid evolution of artificial intelligence (AI) in the field of bioinformatics during 2024–2025, focusing on breakthroughs such as AlphaFold3, foundation models, and AI-driven drug discovery platforms. AI systems have dramatically accelerated biological research — enabling accurate prediction of protein, RNA, and ligand interactions; multi-omics integration; and clinical trial optimization. The Nobel Prize recognition of AlphaFold underscores the global scientific impact of AI in molecular biology. At the same time, companies like DeepMind, Insilico Medicine, and Recursion Pharmaceuticals are reshaping drug discovery with large foundation models trained on trillions of data points. However, despite transformative achievements, challenges persist — particularly in data quality, model interpretability, ethical compliance, and experimental validation. The growing adoption of federated learning and standardized biological databases such as the Polaris platform reflects a major shift toward secure and reliable AI-biomedical collaboration. Overall, 2024–2025 mark a revolutionary turning point, establishing AI not just as a tool but as a foundational paradigm for future medicine, diagnostics, and personalized therapeutics.